PTK6 and breast neoplasm: Compared with the frequency of ErbB2 overexpression (25%–30%), the high frequency of PTK6 expression (60%–86%) in breast tumor cells suggests that this protein has great potential as a new therapeutic target, especially in patients with no ErbB2 expression.